93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group
E. Chen, Leonard W. Seymour(University of Oxford), Derek J. Jonker(University of Ottawa), M. Maclean, Jane Robertson(Cancer Research UK), J M Wells, Sara Mathews
Cited by 2
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Nomenclature for Synthetic Gene Delivery Systems
|Human Gene Therapy|1997|450
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
|European Journal of Cancer|2015|337
Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier
|European Journal of Cancer|1995|334